市場調查報告書
商品編碼
1608880
乳癌近距離治療市場:按技術、按應用、按最終用戶、按地區Breast Cancer Brachytherapy Market, By Technology (High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy), By Application, By End User, By Geography |
預計2024年全球乳癌近距離治療市場規模為8.981億美元,預計2031年將達14.232億美元,2024年至2031年複合年成長率為6.8%。
報告範圍 | 報告詳情 | ||
---|---|---|---|
基準年 | 2023年 | 2024年市場規模 | 8.981 億美元 |
實際資料 | 2019-2023 | 預測期 | 2024年至2031年 |
預測 2024-2031 年複合年成長率: | 6.80% | 2031年價值預測 | 1,423.2 百萬美元 |
乳癌近距離放射治療是放射線治療的一種形式,其中放射性粒子或導管直接放置到乳房組織。這允許將高劑量的輻射傳遞到相關區域,同時限制對周圍健康組織的暴露。這種精準治療在早期、低風險乳癌治療中發揮重要作用,因為它可以實現高治癒率,同時避免通常醜陋的手術。乳房近距離放射治療通常在腫瘤切除術後作為放射加強進行,或單獨用於老年或無法手術的患者。由於人口老化和生活方式的改變,全球乳癌發生率持續上升,乳房近距離放射治療市場預計在未來幾年將穩定成長。
全球乳癌近距離放射治療市場的成長是由全球乳癌發生率上升、人們對保乳治療的偏好增加以及已開發國家對近距離放射治療的有利報銷政策所推動的。然而,向所有類型的患者提供近距離放射治療的困難,加上人們認知到僅靠腫瘤切除術不足以治療,正在阻礙市場潛力。關鍵的市場機會在於擴大乳房近距離放射治療在開發中國家的使用,將其與高風險病例的化療等其他治療方法相結合,並確保放射腫瘤科醫生得到充分的培訓,特別是在資源匱乏的地區。
該報告對全球乳癌近距離放射治療市場進行了詳細分析,並提供了以2023年為基準年的預測期(2024-2031年)的市場規模和年複合成長率(CAGR%)。
它還揭示了各個細分市場的潛在商機,並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
本研究涵蓋的主要企業包括 Varian Medical Systems, Inc.、Elekta AB、Eckert &Ziegler BEBIG、iCAD, Inc.、Hologic, Inc.、Cianna Medical、IsoRay Medical, Inc.、Theragenics Corporation、CR Bard, Inc.、Boston Scientific Corporation、Merit Medical Systems、Cook Medical、SenoRx, Inc.、Nucletron BV 和Xoft, Inc.。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員,如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球乳癌近距離放射治療市場的各種策略矩陣,將促進相關人員的決策。
The global breast cancer brachytherapy market is estimated to be valued at USD 898.1 Mn in 2024 and is expected to reach USD 1,423.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 898.1 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 6.80% | 2031 Value Projection: | 1,423.2 Mn |
Breast cancer brachytherapy is a form of radiation therapy that involves placing radioactive seeds or catheters directly inside breast tissue. It allows the delivery of higher doses of radiation to a contained area while lowering exposure to surrounding healthy tissues. This precision therapy plays an important role in early stage, low risk breast cancer treatment as it can often avoid disfiguring surgery while achieving high cure rates. Breast brachytherapy is typically delivered as radiation boost after lumpectomy, or used alone in elderly or medically inoperable patients. As breast cancer incidence continues rising globally due to aging populations and lifestyle changes, the breast brachytherapy market is positioned for steady growth over the coming years.
The global breast cancer brachytherapy market growth is driven by the rising breast cancer burden worldwide, growing preference for breast conserving therapies, and favorable reimbursement policies in developed countries for brachytherapy procedures. However, the market potential is hampered by difficulties in delivering brachytherapy to all patient types combined with the perception of lumpectomy alone being insufficient treatment. Key market opportunities lie in expanding the use of breast brachytherapy in developing nations, exploring combining it with other treatment modalities like chemotherapy to treat higher risk cases, and ensuring adequate training of radiation oncology specialists especially in low resource settings.
This report provides in-depth analysis of the global breast cancer brachytherapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key companies covered as a part of this study include Varian Medical Systems, Inc., Elekta AB, Eckert & Ziegler BEBIG, iCAD, Inc., Hologic, Inc., Cianna Medical, IsoRay Medical, Inc., Theragenics Corporation, C.R. Bard, Inc., Boston Scientific Corporation, Merit Medical Systems, Cook Medical, SenoRx, Inc., Nucletron B.V., and Xoft, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global breast cancer brachytherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global breast cancer brachytherapy market